Chronic pruritus (itching) of unknown origin (CPUO) is persistent itching that lasts more than 6 weeks without a known cause. It can have a significant impact on quality of life, lead to loss of sleep, and make your daily life much more difficult.
Consider joining our clinical trial
We are conducting a clinical trial to learn if remibrutinib, an investigational oral medicine, can improve itching and benefit people with chronic pruritus (itch) of unknown origin (CPUO) when compared with placebo. A placebo looks like the trial drug but does not have any trial drug in it. Using a placebo helps researchers better understand the effect of a trial drug.
You may or may not benefit directly from being in this trial. This trial may help in developing newer treatment options for the people affected with CPUO. If you benefit from taking remibrutinib at the end of
the clinical trial, you will be offered the option to continue to receive remibrutinib under the extension trial.
Enroll Now
What will this trial help us understand?
How does your itch change over time?
How does your itch-related sleep quality change over time?
How does your itch affect your quality of life in general?
Do you experience any health changes or side effects?
You may be eligible to participate in the trial if you:
- Are 18 years of age or older
- Have had severe CPUO for at least 4 months before joining the trial.
- Have at least 2 body areas (such as trunk, arms, or legs) affected by severe itch.
What to expect if you join the clinical trial:
Evaluation of your itch and overall health, including blood tests
No cost for trial-related treatment, tests, and doctor visits
Initial treatment with 24 weeks of remibrutinib or the placebo, followed by 28 weeks of remibrutinib (no placebo)
Participation support, which may include reimbursement for travel and meals
617-789-5300